Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Cox regression analysis

From: A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

Parameter tested

p-value Hazard ratio [95% CI] (if relevant)

Age

p = 0.1644

Body weight

p = 0.4476

Gender

p = 0.1750

 Female vs Male

1.163 [0.94; 1.45]

ECOG performance status

p < 0.0001

 1: Restricted vs 0: Active

1.76 [1.42; 2.18]

 2: Self-care capable vs 0: Active

3.00 [2.13; 4.22]

 3: Limited self-care capable vs 0: Active

6.91 [3.64; 13.11]

 4: Disabled vs 0: Active

629.65 [56.44; 7024.33]

M Status

p = 0.0005

 M1a vs M1c

0.54 [0.43; 0.81]

 M1b vs M1c

0.66 [0.36; 0.82]

Previous brain metastases

p = 0.2622

 No vs Yes

0.88 [0.71; 1.10]

Treatment naive

p = 0.0114

 No vs Yes

1.29 [1.06; 1.57]

Hospital

p = 0.7601

 Private vs Public

0.965 [0.77; 1.21]

Community

p = 0.5048

 Urban vs Rural

1.07 [0.88; 1.31]